InnoCare Pharma (9969) Q1 2025 earnings summary

Executive summary

• Total revenue for Q1 2025 reached RMB 381 million, up 129.9% year-over-year, driven by orelabrutinib sales and a licensing deal with Prolium.

• Net profit attributable to shareholders was RMB 17.97 million, reversing a net loss in Q1 2024.

• Orelabrutinib sales were RMB 311 million, up 89.2% year-over-year, with new first-line CLL/SLL indication approved and guideline recommendations.

• Strong cash reserves of RMB 7.78 billion as of March 31, 2025, provide operational flexibility and support for clinical development.

• Multiple late-stage clinical trials and regulatory milestones achieved across hematology, autoimmune, and solid tumor pipelines.

Financial highlights

• Gross margin improved to 90.5%, up 5.1 percentage points year-over-year, mainly due to production efficiency and BD income.

• R&D expenses were RMB 208 million, 54.45% of operating revenue, reflecting strategic investment in innovation and clinical trials.

• Achieved quarterly profitability, reversing a net loss of RMB 142.4 million in Q1 2024.

• Net cash flows from operating activities were RMB 56.52 million in Q1 2025.

• Basic and diluted EPS were RMB 0.01 in Q1 2025.

Outlook and guidance

• Anticipates continued strong sales growth, more international collaborations, and multiple NDA/BLA submissions in the next 12 months.

• Sufficient cash reserves to accelerate pipeline development and expand treatment options in China and globally.

• Expects key clinical data readouts and trial initiations for major indications in hematology, autoimmune, and oncology.